Artificial Cells as Living Technology
Prof D A Barrow, Dr O Castell
21 December 2018
The Barrow (Engineering) and Castell (Pharmacy) laboratories at Cardiff University seek motivated PhD candidates to contribute to an exciting €5M funded European collaboration in the field of synthetic biology and the development of programmable artificial cells as living technology.
Targeting the P2X7 purinergic receptor in melanoma (STOKESLU19SF)
Dr L Stokes, Dr C Morris
31 May 2019
There is much research into trying to regain control of cell proliferation or cell death (apoptosis) in cancer. Different strategies exist to do this and a multitude of individual receptor targets are being identified in tumour cell lines and primary cells.
FOXA1 mutations in Lobular Breast Cancer: Reprogramming Responses to Tamoxifen
Prof D Heery, Dr S Johnston
Applications accepted all year round
Tumours of the breast are often hormone-dependent, meaning their growth is driven by steroid hormones such as estrogen. This hormone acts upon the estrogen receptor (ER), which together with other transcription factors such as FOXA1 drives tumour growth.